Phase 2 Systemic Lupus Clinical Trials
38 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 38 trials
Recruiting
Phase 2
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Systemic Lupus ErythematosusLupusLupus Nephritis
Hoffmann-La Roche30 enrolled15 locationsNCT07598396
Recruiting
Phase 1Phase 2
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Refractory Systemic Lupus Erythematosus
Gracell Biotechnologies (Shanghai) Co., Ltd.118 enrolled2 locationsNCT06530849
Recruiting
Phase 2
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Boehringer Ingelheim405 enrolled134 locationsNCT07409181
Recruiting
Phase 2
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Guangdong Hengrui Pharmaceutical Co., Ltd248 enrolled2 locationsNCT07299422
Recruiting
Phase 2
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled54 locationsNCT06570798
Recruiting
Phase 2
A Study of E6742 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Eisai Co., Ltd.256 enrolled17 locationsNCT07515014
Recruiting
Phase 2
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
Active Systemic Lupus Erythematosus
InventisBio Co., Ltd120 enrolled1 locationNCT07311200
Recruiting
Phase 1Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting
Phase 1Phase 2
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
Systemic Lupus ErythematosusLupus Nephritis
Cabaletta Bio28 enrolled23 locationsNCT06121297
Recruiting
Phase 1Phase 2
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Juvenile Myasthenia GravisANCA Associated Vasculitis (AAV)Juvenile Dermatomyositis+1 more
Cartesian Therapeutics50 enrolled2 locationsNCT07089121
Recruiting
Phase 1Phase 2
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
Lupus NephritisRefractory Systemic Lupus Erythematosus
Beijing Biotech24 enrolled1 locationNCT07523542
Recruiting
Phase 2
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Cardiovascular DiseaseSystemic Lupus ErythematosusPremature Atherosclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)45 enrolled1 locationNCT05440422
Recruiting
Phase 2
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Hangzhou Sumgen Biotech Co., Ltd.120 enrolled1 locationNCT07447986
Recruiting
Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSLESLE (Systemic Lupus)+2 more
Ventus Therapeutics U.S., Inc.24 enrolled27 locationsNCT07260877
Recruiting
Phase 2
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Nanjing University School of Medicine50 enrolled1 locationNCT07340463
Recruiting
Phase 1Phase 2
A Study of GR1803 in Systemic Lupus Erythematosus
Systemic Lupus ErthematosusAuto Immune Disease
Genrix (Shanghai) Biopharmaceutical Co., Ltd.44 enrolled1 locationNCT07348055
Recruiting
Phase 1Phase 2
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital18 enrolled1 locationNCT06585514
Recruiting
Phase 2
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
COVID-19Inflammatory Bowel DiseaseRheumatoid Arthritis (RA)+5 more
McGill University Health Centre/Research Institute of the McGill University Health Centre660 enrolled3 locationsNCT06599658
Recruiting
Phase 1Phase 2
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
CAR-T CellSLESystemic Lupus Erythematosus (SLE)+4 more
Children's Hospital of Philadelphia24 enrolled1 locationNCT06839976
Recruiting
Phase 1Phase 2
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
National Heart, Lung, and Blood Institute (NHLBI)78 enrolled1 locationNCT06032923